PE20090107A1 - Anticuerpos de union al antigeno igf-1r - Google Patents

Anticuerpos de union al antigeno igf-1r

Info

Publication number
PE20090107A1
PE20090107A1 PE2008000303A PE2008000303A PE20090107A1 PE 20090107 A1 PE20090107 A1 PE 20090107A1 PE 2008000303 A PE2008000303 A PE 2008000303A PE 2008000303 A PE2008000303 A PE 2008000303A PE 20090107 A1 PE20090107 A1 PE 20090107A1
Authority
PE
Peru
Prior art keywords
seq
antibody
fab
breast
fragment
Prior art date
Application number
PE2008000303A
Other languages
English (en)
Inventor
Michael Neil Burden
Jonathan Henry Ellis
Paul Andrew Hamblin
Alan Peter Lewis
Radha Shah
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0702888.9A external-priority patent/GB0702888D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20090107A1 publication Critical patent/PE20090107A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UN ANTICUERPO, HUMANIZADO O QUIMERICO, O FRAGMENTO DE UNION AL ANTIGENO IGF-1R (RECEPTOR DEL FACTOR DE CRECIMIENTO SIMILAR A INSULINA HUMANO) QUE COMPRENDE LA CDR H3 DE LA SEC ID Nº1 O UNA VARIANTE DE LA MISMA CON UNA O DOS SUSTITUCIONES DE AMINOACIDOS EN LA CDRH3 Y QUE COMPRENDE ADEMAS UNA O MAS DE LAS SECUENCIAS CDRH2: SEC ID Nº2 O CDRH1: SEC ID Nº3, CDRL1: SEC ID Nº4, CDRL2: SEC ID Nº7 Y CDRL3: SEC ID Nº6, DONDE EL ANTICUERPO ES UN ANTICUERPO IgG1 Y EL FRAGMENTO ES UN Fab, Fab', F(ab')2, Fv, DIACUERPO, TRIACUERPO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA CELULA HUESPED TRANSFORMADA, TRANSFECTADA O TRANSDUCIDA. DICHO ANTICUERPO TIENE FUNCIONES EFECTORAS O DE ACTIVACION DE COMPLEMENTO Y/O ADCC (CITOTOXICIDAD CELULAR DEPENDIENTE DEL ANTICUERPO) REDUCIDA Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, PSORIASIS, CANCERES TALES COMO CANCER DE MAMA, PROSTATA, PULMON, ENTRE OTROS
PE2008000303A 2007-02-14 2008-02-12 Anticuerpos de union al antigeno igf-1r PE20090107A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0702888.9A GB0702888D0 (en) 2007-02-14 2007-02-14 Novel Antibodies
US95321007P 2007-08-01 2007-08-01

Publications (1)

Publication Number Publication Date
PE20090107A1 true PE20090107A1 (es) 2009-03-20

Family

ID=42025950

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000303A PE20090107A1 (es) 2007-02-14 2008-02-12 Anticuerpos de union al antigeno igf-1r

Country Status (5)

Country Link
JP (1) JP2010518140A (es)
KR (1) KR20090114449A (es)
EA (1) EA200900991A1 (es)
MX (1) MX2009008754A (es)
PE (1) PE20090107A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5972176B2 (ja) 2010-02-23 2016-08-17 サノフイ 抗アルファ２インテグリン抗体及びそれらの使用
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
EP2791338B1 (en) * 2011-12-15 2019-02-20 The Royal Institution for the Advancement of Learning / McGill University Soluble igf receptor fc fusion proteins and uses thereof
JP6959229B2 (ja) * 2015-10-23 2021-11-02 アポジェニックス アーゲー 一本鎖ｇｉｔｒ受容体アゴニストタンパク質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275446A3 (en) * 2001-01-05 2012-08-15 Pfizer Inc. Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7638605B2 (en) * 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
WO2005058967A2 (en) * 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications

Also Published As

Publication number Publication date
EA200900991A1 (ru) 2010-02-26
MX2009008754A (es) 2009-11-02
JP2010518140A (ja) 2010-05-27
KR20090114449A (ko) 2009-11-03

Similar Documents

Publication Publication Date Title
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
JP2020500538A5 (es)
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
NZ623347A (en) Novel anti-dr5 antibody
NZ603972A (en) Anti-fgfr2 antibodies
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
IL259940B2 (en) A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
IL276695A (en) Antibodies, pharmaceuticals and their uses
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20141660A1 (es) PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA
AR086579A1 (es) Proteinas de union a antigeno
PE20090368A1 (es) Anticuerpos anti-igf
RU2020111366A (ru) Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения
RU2008101772A (ru) Антагонисты рецепторов для лечения метастатического рака
AR061115A1 (es) Anticuerpos anti- interleuquina 18 (il-18)
RU2013152164A (ru) Анти-в7-н3-антитело
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
AR073770A1 (es) Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
PE20170687A1 (es) Proteinas de enlace a cd127
NZ568403A (en) CD20-specific antibodies and methods of employing same
RU2011108260A (ru) Фармацевтическая композиция для лечения и профилактики злокачественных опухолей

Legal Events

Date Code Title Description
FC Refusal